French biotech EDAP (EDAP +14.4%) closes a $9.3M direct offering of ordinary shares at $3.11/ADS. Proceeds will be used to advance the preparatory activities related to the Ablatherm HIFU PMA and upcoming Gastroenterology and Urology Devices Ad Comm meeting on July 30 and to expand its U.S. operations to promote Ablatherm HIFU post approval. The device was CE Mark-approved in 2000.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs